Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 7/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980971 | 0.91 | KDM4E (0.40) | IDH1SCN9ATSHRSMN1; SMN2PIK3CA | |
| SCHEMBL8256507 | 0.88 | SCN9A (0.43) | IDH1SCN9ASMN1; SMN2PIK3CAMTOR | |
| SCHEMBL8349969 | 0.85 | BPTF (0.43) | SCN9ATSHRPIK3CAMTORCMA1 | |
| SCHEMBL16703464 | 0.83 | RAD52 (0.45) | TSHRPIK3CAMTORCMA1CCNC | |
| SCHEMBL850221 | 0.81 | TSHR (0.50) | TSHRSMN1; SMN2PIK3CAMTORCMA1 | |
| SCHEMBL18493886 | 0.81 | IDH1 (0.48) | IDH1PIK3CAMTORCMA1CCNC | |
| SCHEMBL15499081 | 0.79 | PKM (0.48) | SCN9ASMN1; SMN2CMA1CCNCCDK8 | |
| SCHEMBL3448892 | 0.79 | DGAT1 (0.41) | PIK3CAMTORCMA1CCNCCDK8 | |
| SCHEMBL17151142 | 0.79 | PIK3CA (0.47) | PIK3CAMTORCMA1CCNCCDK8 | |
| SCHEMBL8303857 | 0.79 | TP53 (0.39) | SCN9ASMN1; SMN2PIK3CAMTORCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | IDH1 2010/4885SCN9A 4858/4885TSHR 4324/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | IDH1 1103/4885SCN9A 4126/4885TSHR 4161/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | IDH1 1103/4885SCN9A 4126/4885TSHR 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.